Denali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from Analysts at Robert W. Baird

Stock analysts at Robert W. Baird initiated coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a report issued on Tuesday,Benzinga reports. The firm set an “outperform” rating and a $31.00 price target on the stock. Robert W. Baird’s price objective suggests a potential upside of 56.41% from the stock’s previous close.

Several other equities research analysts also recently commented on DNLI. Jefferies Financial Group boosted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a report on Monday, December 16th. William Blair started coverage on shares of Denali Therapeutics in a report on Friday. They set an “outperform” rating for the company. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Finally, JPMorgan Chase & Co. cut their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $39.27.

Denali Therapeutics Trading Down 6.8 %

NASDAQ:DNLI opened at $19.82 on Tuesday. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33. The stock has a market capitalization of $2.85 billion, a price-to-earnings ratio of -7.18 and a beta of 1.39. The firm has a fifty day simple moving average of $24.46 and a two-hundred day simple moving average of $24.89.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the business posted ($0.72) earnings per share. Equities analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the transaction, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the sale, the insider now directly owns 178,066 shares in the company, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,658 shares of company stock valued at $1,667,943 over the last three months. Corporate insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC grew its stake in shares of Denali Therapeutics by 43.6% during the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC bought a new position in Denali Therapeutics during the third quarter worth about $73,000. Assetmark Inc. boosted its position in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at approximately $194,000. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.